에 대한 최신 뉴스 Processa Pharma (NASDAQ:PCSA) 주식

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ANGO

BIGC

LEVI

PCSA

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 컨스텔레이션 브랜드(NYSE:STZ)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.

목요일 주목해야 할 주식: 컨스텔레이션 브랜드, 리바이 스트라우스 그리고 3종목

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

Management

TSLA

Tesla Chief Information Officer Nagesh Saldi Is Leaving Company

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Islamic Resistance In Iraq Says It Attacked Target In South Israel

Palantir Technologies Inc (NYSE: PLTR) shares climbed 3.6% on Thursday after reports from the previous day that co-founder and chairman Peter Thiel has completed selling the maximum number of shares allowed under his trading plan set in May,<a href="https://www.benzinga.com/news/24/10/41145602/palantir-stock-is-moving-higher-wednesday-whats-going-on"> according to Barron's.</a>
The company&#8217;s recent success brings to mind Jim Cramer's evolving stance on Palantir. He once dismissed it as not even a &#8220;real company.&#8221; Less than a month later, he completely&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/23/04/32017123/john-oliver-joins-inverse-jim-cramer-craze-says-youd-live-50-years-after-cramer-predicts-y">changed his mind</a>.
What Happened:&nbsp;Palantir&nbsp;announced an expansion of its&nbsp;<a href="https://www.benzinga.com/news/23/04/31676496/whats-going-on-with-palantir-technologies-stock-today">partnership</a>&nbsp;with&nbsp;Microsoft Corp&nbsp;(NASDAQ:&nbsp;<a href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) in early 2023. Following the announcement, Cramer said the AI-focused data software company was really just a &#8220;series of press releases&#8221; made up&nbsp;<a href="https://www.benzinga.com/news/23/04/31684804/jim-cramer-trashes-palantir-c3-ai-says-they-arent-even-real-companies">for the &#8220;memesters.&#8221;</a>
He complained about Palantir CEO&nbsp;Alex Karp&#8217;s&nbsp;use of foul language on conference calls and said the company would be a lot more legitimate if Karp would &#8220;stop dropping F-bombs.&#8221;
About a month later, Palantir <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32293202/palantir-just-beat-earnings-and-the-stock-is-ripping-but-4-analysts-are-mixed">reported strong quarterly results</a> and Cramer quickly changed his mind on the Karp-led company.
&#8220;I&#8217;ve been very critical of Alex Karp and not just because I thought it was totally unnecessary for him to curse on the conference call, but they had been losing money hand over fist,&#8221; Cramer said at the time on CNBC&#8217;s &#8220;Squawk On The Street.&#8221;
&#8220;They made money, $17 million, and they actually forecast GAAP positive, and what they did is pivot.&#8221;
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40937841/jim-cramer-this-utilities-stock-is-a-buy-calls-wells-fargo-a-winner">Jim Cramer: This Utilities Stock Is A Buy, Calls Wells Fargo A &#8216;Winner&#8217;</a>
Previously, Palantir didn&#8217;t care about making money and&nbsp;the company was all about &#8220;world domination,&#8221; Cramer said: &#8220;They did the pivot that we have all been hoping for. It was a clear pivot and I think the stock should be up.&#8221;
In a letter to shareholders, Karp said he&nbsp;expected Palantir&nbsp;<a href="https://www.benzinga.com/news/earnings/23/05/32286656/why-palantir-stock-is-ripping-higher-today">to&nbsp;remain profitable</a>&nbsp;in each quarter&nbsp;through the end of 2023. The stock was up more than 20% on the heels of the company&#8217;s bullish forecast.
Cramer noted that he plans to take a closer look at the company now that it&#8217;s actually making money. He also expressed interest in what Palantir is doing for Ukraine in the ongoing war with Russia before highlighting new&nbsp;<a href="https://www.benzinga.com/news/earnings/23/05/32273478/palantir-delivers-another-profitable-quarter-touts-new-ai-platform-shares-surge">AI technology</a>&nbsp;that allows Palantir to&nbsp;&#8220;control the battlefield&#8221;:
&#8220;Look out,&nbsp;Russia,&#8221; Cramer said.
On a conference call with investors and analysts, Palantir said Ukrainian forces have been unleashing&nbsp;the company&#8217;s AI products with incredible speed.
&#8220;The future has already arrived,&#8221; the&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32293202/palantir-just-beat-earnings-and-the-stock-is-ripping-but-4-analysts-are-mixed">company stated</a>.
PLTR Price Action: When Cramer turned positive on Palantir in early 2023, the stock was trading below $10. Palantir shares were up 3.6%, trading at $38.87 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/23/04/31703954/early-palantir-investor-claps-back-at-jim-cramer-for-ludicrous-comments-says-palantir-st">Early Palantir Investor Claps Back At Jim Cramer For &#8216;Ludicrous&#8217; Comments, Says Palantir Stock Will More Than &#8216;Triple&#8217;</a></li>
</ul>
Photo: Flickr/Shutterstock.&nbsp;
Some elements of this story were previously reported by Benzinga and it has been updated.

Tech

General

PLTR

Jim Cramer Once Told Palantir CEO To 'Stop Dropping F-Bombs,' Then He Realized The Future Had 'Already Arrived'

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has recalled <a href="https://www.benzinga.com/topic/cybertruck" target="_blank" rel="noreferrer noopener">certain 2024 Cybertruck models.</a>
The <a target="_blank" href="https://www.nhtsa.gov/search-safety-issues#recall" rel="noreferrer noopener">recall </a>of around 27,185 Cybertrucks is due to a delay in the rearview camera image when shifting into reverse, which causes these vehicles to not meet the Federal Motor Vehicle Safety Standard (FMVSS) number 111 regarding &#8220;Rear Visibility.&#8221;
To address the issue, Tesla has issued a free over-the-air (OTA) software update. Notification letters to owners are expected to be mailed out on November 25.
Earlier in June, the EV giant recalled over 11,000&nbsp;Cybertrucks&nbsp;over concerns that its sail applique may come loose or detach from the vehicle while it is moving and nearly 12,000 Cybertrucks over <a target="_blank" href="https://www.benzinga.com/news/24/06/39473764/tesla-recalls-more-than-11-000-cybertrucks-over-applique-detachment-risk-and-nearly-12-000-for-winds" rel="noreferrer noopener">concerns that their windshield wiper might stop working</a>.
Read Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/09/40985179/tesla-model-y-could-end-fords-long-reign-as-americas-top-selling-vehicle-will-2024-be-the-year" rel="noreferrer noopener">Tesla Model Y Could End Ford's Long Reign As America's Top-Selling Vehicle: Will 2024 Be The Year?</a>
In April, Tesla recalled&nbsp;3,878 Cybertruck vehicles over concerns of unintentional acceleration. The company had said in a filing with the U.S. auto safety regulator&nbsp;National Highway Traffic Safety Administration that the accelerator pedal pad on the affected vehicles may dislodge and become trapped by the interior trim above the pedal, <a target="_blank" href="https://www.benzinga.com/government/24/04/38331377/tesla-recalls-over-3-800-cybertrucks-citing-unintended-acceleration-risk" rel="noreferrer noopener">thereby causing it to accelerate without the driver intending to.</a>
Tesa commenced deliveries of its&nbsp;Cybertruck&nbsp;in Mexico last month, making it the first country outside the U.S. <a target="_blank" href="https://www.benzinga.com/news/24/09/41039631/tesla-begins-cybertruck-deliveries-in-mexico-before-canada-first-country-to-get-the-stainless-steel" rel="noreferrer noopener">where the stainless steel truck is delivered.</a>
Tesla reported third-quarter deliveries&nbsp;of 462,890 vehicles, up 6.4% year-over-year and <a target="_blank" href="https://www.benzinga.com/news/24/10/41141444/tesla-stock-plunges-3-despite-q3-deliveries-exceeding-consensus-and-growing-year-over-year" rel="noreferrer noopener">up 4.3% quarter-over-quarter.</a>
The company reported third-quarter production of 469,796 vehicles, up 9.1% year-over-year and up 14.4% quarter-over-quarter.
Price Action: TSLA shares are trading lower by 2.31% to $243.26 at last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41145803/tesla-q3-deliveries-step-in-the-right-direction-analyst-says-more-heavy-lifting-nee" target="_blank" rel="noreferrer noopener">Tesla Q3 Deliveries &#8216;Step In The Right Direction&#8217;: Analyst Says More &#8216;Heavy Lifting&#8217; Needed From Elon Musk To Turn Growth Story Around</a></li>
</ul>

Equities

Tesla Recalls 27,185 Cybertruck Vehicles Over Rearview Camera Delay

California's recent emergency rules severely <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">limiting hemp-derived products</a> are making waves across the cannabis industry. Gov. Gavin Newsom&#8216;s swift action has already begun to reshape the market, raising concerns about its broader impact on businesses and consumers.
The emergency rules aimed at limiting unregulated hemp products, particularly those containing THC, have been met with mixed reactions. While some believe it is a necessary step toward ensuring product safety, others are worried about the long-term consequences for businesses that rely on these products.
<h1 class="wp-block-heading">Impact on Public Safety and Market Stability</h1>
Bryan Gerber, CEO of Hara Supply and upcoming speaker at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>, weighed in on the situation, explaining that while the ban might be disruptive, it also addresses a critical issue. 
&#8220;Governor Newsom&#8217;s ban on hemp THC products in California will have a significant effect on the state&#8217;s market, given the category&#8217;s prevalence in a variety of legal adult-use and medical products,&#8221; Gerber said.
He highlighted the health risks associated with unregulated products, which he believes are not being adequately controlled. &#8220;As these products are not currently regulated properly, they undoubtedly pose potential health risks, and upholding the highest standards of public safety should be a non-negotiable for cannabis regulators and the industry at large.&#8221;
The immediacy of the ban has already sent shockwaves across California's supply chain, particularly as it exposes how unregulated products have infiltrated the legal market. However, Gerber is optimistic that the ban could lead to a safer marketplace. 
&#8220;Banning this category until legitimate regulations are implemented is better for the market,&#8221; he noted. Gerber believes that ensuring safe, tested hemp THC from vetted companies is what consumers deserve and will ultimately strengthen the legal market.
<h1 class="wp-block-heading">Overall Regulatory Implications</h1>
California's decision could also set the tone for future regulations in other states and at the federal level. 
&#8220;How California navigates this ban could inform future regulatory and business decisions across the country,&#8221; Gerber explained. Federal legislation, including the 2018 Farm Bill, may face increased scrutiny as regulators assess the impact of hemp-derived THC products.
The path forward remains uncertain as industry leaders and businesses adapt to these new regulations. While some may struggle under the weight of these restrictions, others are hopeful that a more regulated market will benefit consumers and create a safer environment for cannabis products across the U.S.
Photo: Benzinga edit with images by Bureau of Reclamation via Wikimedia Commons and Rob Warner on Unsplash

Cannabis

Government

Events

Exclusives

Interview

California's Hemp Restrictions Spark Industry Debate: 'Banning This Category Is Better For The Market,' Says Expert

Financial giants have made a conspicuous bullish move on Starbucks. Our analysis of options history for Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) revealed 11 unusual trades.
Delving into the details, we found 54% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $1,603,569, and 3 were calls, valued at $96,080.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $105.0 for Starbucks, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Starbucks options trades today is 4275.2 with a total volume of 5,239.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Starbucks's big money trades within a strike price range of $85.0 to $105.0 over the last 30 days.
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727972432_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.15</td>
<td>$10.95</td>
<td>$11.0</td>
<td>$95.00</td>
<td>$1.1M</td>
<td>6.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.75</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$95.00</td>
<td>$210.5K</td>
<td>2.6K</td>
<td>468</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$98.00</td>
<td>$105.0K</td>
<td>565</td>
<td>1</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$1.98</td>
<td>$1.71</td>
<td>$1.8</td>
<td>$95.00</td>
<td>$44.9K</td>
<td>554</td>
<td>3</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.4</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$95.00</td>
<td>$40.5K</td>
<td>6.6K</td>
<td>102</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
Having examined the options trading patterns of Starbucks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Starbucks</h3>
<ul>
<li>With a trading volume of 1,666,427, the price of SBUX is down by -0.63%, reaching $95.89.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 28 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Starbucks</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $103.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has elevated its stance to Outperform, setting a new price target at $115. 
&#x2A; An analyst from Jefferies has revised its rating downward to Underperform, adjusting the price target to $76. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Buy, adjusting the price target to $110. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Starbucks, targeting a price of $110. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Starbucks, maintaining a target price of $105. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

SBUX

Starbucks Options Trading: A Deep Dive into Market Sentiment

Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $93,000, and 6 were calls, valued at $314,820.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $32.0 for Pfizer over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 7268.62 with a total volume of 11,974.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Pfizer's big money trades within a strike price range of $28.0 to $32.0 over the last 30 days.
<h3>Pfizer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727972427_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.45</td>
<td>$0.44</td>
<td>$0.45</td>
<td>$30.00</td>
<td>$112.5K</td>
<td>16.8K</td>
<td>3.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.0</td>
<td>$4.15</td>
<td>$5.0</td>
<td>$30.00</td>
<td>$60.0K</td>
<td>247</td>
<td>4</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$0.32</td>
<td>$0.3</td>
<td>$0.31</td>
<td>$30.00</td>
<td>$48.4K</td>
<td>1.6K</td>
<td>296</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.62</td>
<td>$2.61</td>
<td>$2.62</td>
<td>$32.00</td>
<td>$47.1K</td>
<td>256</td>
<td>180</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.49</td>
<td>$0.48</td>
<td>$0.49</td>
<td>$28.50</td>
<td>$47.1K</td>
<td>656</td>
<td>6.9K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Pfizer</h3>
<ul>
<li>With a trading volume of 10,723,798, the price of PFE is down by -0.93%, reaching $28.34.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 26 days from now.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $45.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Pfizer's Latest Options Trends

Deep-pocketed investors have adopted a bearish approach towards United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in X usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for United States Steel. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 52% bearish. Among these notable options, 13 are puts, totaling $1,496,460, and 4 are calls, amounting to $133,520.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $52.5 for United States Steel during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in United States Steel's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to United States Steel's substantial trades, within a strike price spectrum from $25.0 to $52.5 over the preceding 30 days.
<h3>United States Steel Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727972422_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.2</td>
<td>$40.00</td>
<td>$183.9K</td>
<td>5.6K</td>
<td style="text-align: right;">802</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.2</td>
<td>$40.00</td>
<td>$183.9K</td>
<td>5.6K</td>
<td style="text-align: right;">602</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.2</td>
<td>$40.00</td>
<td>$183.9K</td>
<td>5.6K</td>
<td style="text-align: right;">402</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.75</td>
<td>$15.6</td>
<td>$15.9</td>
<td>$50.00</td>
<td>$157.4K</td>
<td>7.3K</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.0</td>
<td>$15.6</td>
<td>$16.0</td>
<td>$50.00</td>
<td>$156.8K</td>
<td>7.3K</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About United States Steel</h3>
United States Steel Corp operates primarily in the United States but also has a steelmaking capacity in Slovakia. The company's operating segments include North American Flat-Rolled (Flat-Rolled), Mini Mill, U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment includes U. S. Steel's integrated steel plants and equity investees in North America involved in the production of slabs, strip mill plates, sheets, and tin mill products, as well as all iron ore and coke production facilities in the United States. It primarily serves North American customers in the service center, conversion, transportation, construction, container, and appliance, and electrical markets.
<h3>Present Market Standing of United States Steel</h3>
<ul>
<li>With a volume of 768,153, the price of X is up 0.9% at $34.91. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>Professional Analyst Ratings for United States Steel</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $40.52333333333333.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on United States Steel with a target price of $41. 
&#x2A; Showing optimism, an analyst from GLJ Research upgrades its rating to Buy with a revised price target of $38. 
&#x2A; Showing optimism, an analyst from JP Morgan upgrades its rating to Overweight with a revised price target of $42. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for United States Steel with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On United States Steel

WIIM

AMZN

NFLX

PARA

Shares of streaming companies are trading lower after Amazon announced they will ramp up their Prime Video advertising spend.

In 1989, a couple from Long Island took a chance on an unclaimed storage unit for just $100, as reported by a CNBC article. They didn't expect to find a piece of movie history tucked away under some old blankets – a 1976 Lotus Esprit, used in the James Bond film The Spy Who Loved Me.
The couple, who had no clue what they stumbled upon, initially planned to fix the car's roof and do some minor work. But while hauling it home, truckers on the road started radioing them, letting them know they had something much more valuable – a James Bond car. After hearing this, the husband rented the movie and realized they were sitting on a treasure.&nbsp;
Don't Miss:
<ul>
<li>Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million with just $500</a>.</li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Ironically, the couple had reportedly never even seen a Bond film.&nbsp;
Years later, after some cosmetic touch-ups, they auctioned the car in 2013. That's when Elon Musk entered the picture, paying nearly $1 million for the Lotus – $997,000. Musk, who grew up watching the Bond movie, said, "It was amazing as a little kid to watch James Bond drive the Lotus Esprit off a pier and have it transform into a submarine."
In a statement to auto blog Jalopnik, Musk said, "I was disappointed to learn that it can&#8217;t transform. What I&#8217;m going to do is upgrade it with a Tesla electric powertrain and try to make it transform for real."
Interestingly, the car, nicknamed "Wet Nellie," was originally converted into a functional submarine for the movie, costing over $100,000. While it couldn't drive on land, it was fully capable of underwater action with propellers and ballast tanks. Instead of wheels, it had "articulated fins.&#8221;&nbsp;
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Musk's fascination with the Lotus Esprit didn't end at its purchase. He stated that the car significantly shaped the futuristic design of Tesla's Cybertruck, unveiled in 2019.&nbsp;
Musk <a href="https://x.com/elonmusk/status/1197638937109336066">posted on X</a> that the Cybertruck's sharp, angular design was "influenced partly" by the iconic Bond car, writing: "Cybertruck design influenced partly by The Spy Who Loved Me." He attached a YouTube clip of the movie.&nbsp;
Musk's desire to combine cutting-edge electric vehicle technology with a design inspired by his childhood memories of James Bond highlights the seamless blend of nostalgia and innovation at the heart of Tesla's boldest creations.
Read Next:
<ul>
<li>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Elon Musk Paid $1 Million For A 1976 Car That Inspired Cybertruck's Design – Seller Originally Bought It For Just $100 In A Storage Unit Sale

Morgan Stanley analyst Brian Nowak reiterated Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with an Overweight rating and a <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">$210&nbsp;price target</a>.
Amazon traded at 22 times Nowak&#8217;s 2026 free cash flow, representing 29% growth (fiscal 2024-2026 free cash flow per share CAGR). He said this is a ~30% discount to Amazon&#8217;s mega-cap tech peer median growth-adjusted multiple on a growth-adjusted basis.
Also Read: <a href="https://www.benzinga.com/news/24/10/41162084/amazon-prime-video-ramps-up-ads-taking-on-netflix-and-disney-in-streaming-battle" target="_blank" rel="noreferrer noopener">Amazon Prime Video Ramps Up Ads, Taking on Netflix and Disney+ in Streaming Battle</a>
The price target implies paying 20 times fiscal 2027 free cash flow for 24% growth (fiscal 2025-2027 free cash flow per share CAGR) and 0.8 times on a growth-adjusted basis, a ~20% discount to Amazon&#8217;s mega-cap tech peer median growth-adjusted multiple of 1.1 times.
Nowak noted the tactical risk to fourth-quarter EBIT but is buying weakness into fiscal 2025 as the profit challenges are temporary and not structural.
Nowak said Amazon&#8217;s growing focus on lower-priced, lower-margin essentials drives merchandise margin pressure, which is holding back the near-term slope of its North American retail profit ramp. Expected discounting in a competitive holiday season creates further near-term uncertainty, he said.
According to the analyst, Amazon makes low-priced essentials profitable and the cost to serve still leads to $8-$9 free cash flow per share. Corporate efficiencies could lead to $2 billion-$4 billion of further savings, and Project Kuiper and headcount models speak to minimal headwinds here.
Nowak said Amazon management&#8217;s recent letter outlining an increased focus on efficiency should lead to a further EBIT cushion and upside in fiscal 2025.
Project Kuiper is likely to be manageable from a P&amp;L-impact perspective, Nowak said. He noted Amazon&#8217;s growing net cash balance creates a higher probability of capital returns in fiscal 2025.
Nowak projected fiscal 2024 revenue of $633.96 billion and EPS of $4.80. He expects fiscal 2025 revenue of $ 697.94 billion and EPS of $5.93.
AMZN Price Action:&nbsp;Amazon stock is down 1.15% at $182.64 at publication Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41163890/alibaba-and-jd-com-battle-for-hong-kong-shoppers-stocks-slid-after-stimulus-rally" target="_blank" rel="noreferrer noopener">Alibaba and JD.com Battle for Hong Kong Shoppers, Stocks Slide After Stimulus Rally</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

Analyst Ratings

Amazon's Profitable Essential Merchandise, Efficiency Gains Set To Drive Growth: Analyst

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday.
Following the market opening Thursday, the Dow traded up 0.16% to 17,954.10 while the NASDAQ gained 0.43% to 18,002.24. The S&amp;P 500 also fell, dropping, 0.03% to 5,707.82.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41161390/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-divi">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 1.3% on Thursday.
In trading on Thursday, materials shares dipped by 0.9%.
Top Headline
The S&amp;P Global services PMI was revised lower to 55.2 in September compared to a preliminary reading of 55.4, and versus a reading of 55.7 in August.
The S&amp;P Global U.S. composite PMI sipped to 54 in September versus a preliminary reading of 54.4, and versus 54.6 in August.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares shot up 67% to $0.1416 after the company announced its subsidiary, Elevai Biosciences, filed two patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients.</li>
<li>Shares of Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) got a boost, surging 47% to $1.8253 after the company announced the Data and Safety Monitoring Committee&#8217;s review outcome for its Phase 1b/2a clinical trial of SYN-004. The DSMC has recommended the study proceed to enroll cohort 3.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares were also up, gaining 39% to $0.1601.</li>
</ul>
Equities Trading DOWN
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares dropped 19% to $6.21 following first-quarter results.</li>
<li>Shares of Kaixin Holdings &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) were down 11% to $0.3042. Shares of US-listed Chinese stocks traded lower as the sector pulled back from recent strength. These companies rallied after the People&#8217;s Bank of China announced a new stimulus package ahead of the Golden Week holidays.</li>
<li>Ingevity Corporation &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) was down, falling 14% to $32.22 as the company said John Fortson has departed as president and CEO and from the board of directors of the company, effective as of Oct. 2.</li>
</ul>
Commodities In commodity news, oil traded up 4.3% to $73.14 while gold traded down 0.1% at $2,667.50.
Silver traded up 0.3% to $32.015 on Thursday, while copper fell 2% to $4.5540.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.79%, Germany's DAX fell 0.69% and France's CAC 40 fell 0.97%. Spain's IBEX 35 Index rose 0.18%, while London's FTSE 100 fell 0.07%.
Producer prices in the Eurozone rose 0.6% month-over-month in August compared to a revised 0.7% increase in July. The HCOB Eurozone composite PMI was revised higher to 49.6 in September versus a preliminary reading of 48.9.
The S&amp;P Global UK services PMI declined to 52.4 in September from 53.7 in the previous month, while German services PMI fell to 50.6 in September from 51.2 a month ago.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 gaining 1.97%, Hong Kong's Hang Seng Index falling 1.47% and India's BSE Sensex dipping 2.10%.
The au Jibun Bank Japan services PMI was revised lower to 53.1 for September, versus a preliminary reading of 53.9.
Economics
<ul>
<li>U.S. initial jobless claims increased by 6,000 from the prior week to 225,000 during the week ended Sept. 28, compared to market estimates of 220,000.</li>
<li>The S&amp;P Global services PMI was revised lower to 55.2 in September compared to a preliminary reading of 55.4, and versus a reading of 55.7 in August.</li>
<li>The S&amp;P Global U.S. composite PMI sipped to 54 in September versus a preliminary reading of 54.4, and versus 54.6 in August.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41160677/top-3-consumer-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

ELAB

KXIN

NGVT

TOVX

Crude Oil Jumps Over 4%; US Services PMI Revised Lower

YPF Sociedad An&oacute;nima (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ypf#NYSE">YPF</a>), Argentina&#39;s state-owned energy company, has announced that it will be lowering fuel prices across the country, starting from Oct. 1, 2024. The company announced a 4% reduction in gasoline prices and a 5% reduction in diesel prices. However, the pump prices will reflect a 1% reduction in gasoline prices and 2% in diesel prices. The devaluation of the Argentine peso and an increase in taxes led to a 3% rise in fuel prices, which partially reduced the full benefit of the price cut.
<h2>YPF&#39;s Fair Pricing Strategy</h2>
YPF considers several factors before setting the prices, including local and international market dynamics as well as fuel production costs as it intends to stick to a fair pricing strategy for fuels. Per the company&#39;s statement, the reduction in fuel prices is a reflection of the declining trend in the global Brent crude oil prices. The state-owned energy firm has reportedly lowered fuel prices for the first time since 2019.
Argentina has witnessed a cumulative 51% rise in gasoline prices so far. According to source, the year-over-year increase in gas prices stood at a staggering 340% in September. YPF has successfully struck a balance between local fuel prices and international prices over the past eight months, which should enable it to make future price adjustments based on international Brent crude prices alongside other local factors associated with costs.
<h2>Economic Challenges in Argentina</h2>
Argentina has been grappling with a high rate of inflation and instability in the value of its currency. As such, the reduction in fuel prices may have a significant impact on the economy. Easing up fuel prices by YPF should reduce the burden on Argentina&#39;s consumers and its businesses by lowering transportation expenses. As Argentina&#39;s largest oil company, YPF&#39;s decision carries substantial weight and may influence other companies in the industry to do the same, benefitting consumers all over Argentina.&nbsp;
<h2>YPF&#39;s Zacks Rank and Key Picks</h2>
Currently, YPF carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the energy&nbsp;sector are&nbsp;PEDEVCO Corp. (AMEX:PED),&nbsp;Archrock Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aroc#NYSE">AROC</a>) and VAALCO Energy (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>). PEDEVCO and Archrock presently sport a Zacks Rank #1 (Strong Buy) each, whereas VAALCO Energy carries a Zacks Rank #2 (Buy).
PEDEVCO is engaged in the acquisition and development of energy assets in the United States and Pacific Rim countries. PED stands to benefit from its holdings in the Permian Basin, one of the most prolific oil-producing regions in the United States, as well as in the D-J Basin in Colorado, which includes more than 150 high-quality drilling locations. Combined with bullish oil prices, this is expected to boost the company&#39;s production and overall profitability.
Archrock is an energy infrastructure company based in the United States, with a focus on midstream natural gas compression. It provides natural gas contract compression services and generates stable fee-based revenues.
VAALCO Energy is an independent energy company, involved in upstream business operations with a diversified presence in Africa and Canada and have a large inventory of drilling locations in the premium Acreage.
<a href="https://www.zacks.com/stock/news/2345294/ypf-reduces-fuel-prices-amid-inflationary-pressures-in-argentina?cid=CS-BENZ-FT-analyst_blog|company_news_energy_sector-2345294">To read this article on Zacks.com click here.</a>

Mid Cap

Penny Stocks

Contracts

Small Cap

AROC

YPF Reduces Fuel Prices Amid Inflationary Pressures in Argentina

JP Morgan analyst Jimmy Bhullar maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Overweight and lowers the price target from $65 to $63.

JP Morgan Maintains Overweight on Unum Gr, Lowers Price Target to $63

JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) with a Overweight and lowers the price target from $20 to $18.

SRRK

JP Morgan Maintains Overweight on Scholar Rock Holding, Lowers Price Target to $18

Cantor Fitzgerald analyst Brett Knoblauch reiterates TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Overweight and maintains $10 price target.

WULF

Cantor Fitzgerald Reiterates Overweight on TeraWulf, Maintains $10 Price Target

JP Morgan analyst Arun Jayaram maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Overweight and lowers the price target from $23 to $22.

JP Morgan Maintains Overweight on NOV, Lowers Price Target to $22

<a href="https://blog.youtube/news-and-events/tall-updates-coming-to-shorts/" title="https://blog.youtube/news-and-events/tall-updates-coming-to-shorts/">https://blog.youtube/news-and-events/tall-updates-coming-to-shorts/</a>

GOOG

GOOGL

YouTube Says Starting Oct 15, Can Upload Shorts Up To 3 Minutes Long

JP Morgan analyst Jeffrey Zekauskas maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Neutral and raises the price target from $120 to $126.

JP Morgan Maintains Neutral on RPM Intl, Raises Price Target to $126

JP Morgan analyst Jimmy Bhullar maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Neutral and raises the price target from $220 to $222.

JP Morgan Maintains Neutral on Reinsurance Gr, Raises Price Target to $222

Processa Pharmaceuticals appoints CFO

Processa Pharmaceuticals (PCSA) has provided an update. Processa Pharmaceuticals, Inc. has appointed seasoned industry expert Russell Skibsted as t...

Processa Pharmaceuticals Welcomes New CFO Russell Skibsted

FDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is rising higher on Tuesday after the company <a href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-fda-clearance-120000203.html">posted an update</a> from the Food and Drug Administration (FDA).



The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company&rsquo;s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.



With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.



David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.




&ldquo;We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.&rdquo;




<h2>PCSA Stock Movement Today</h2>



With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company&rsquo;s daily average trading volume of about 90,000 shares.



PCSA stock is up 29.4% as of Tuesday morning.



Investors seeking out even more of the most recent stock market stories are going to want to stick around!



We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what&rsquo;s happening with shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Delta&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/dal-stock-quote/">DAL</a>) and SoFi&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) stock today. All of that news is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>



<li><a href="https://investorplace.com/2024/07/dal-stock-delta-wants-crowdstrike-to-pay-up-for-flight-delays-caused-by-outage/">DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</a></li>



<li><a href="https://investorplace.com/2024/07/sofi-stock-sofi-just-raised-its-profit-guidance-again-whats-going-on/">SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What&rsquo;s Going On?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is still rallying higher as a bankruptcy filing has introduced an immense amount of volatility to the online education platform company&rsquo;s shares.



Today&rsquo;s movement has TWOU stock rallying 15.5% as of Tuesday morning. That comes with more than 31 million shares changing hands. For the record, its daily average trading volume is about 2.5 million shares.



The rally today <a href="https://investorplace.com/2024/07/2u-twou-stock-pops-more-than-100-despite-bankruptcy-filing/">follows a surge yesterday</a> that saw the stock jump as more than 100% higher during normal trading hours. It is worth noting that these rallies come after the stock suffered a roughly 60% drop when news of its bankruptcy broke.



<h2>What&rsquo;s Next for 2U Stock?</h2>



2U is using this bankruptcy to <a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">restructure its debt</a> via deals with lenders. This has the company continuing operations throughout the process. It expects to exit bankruptcy by the end of September.



It&rsquo;s also unclear how this bankruptcy filing will affect TWOU stock. While the company is only using it for restructuring, it could cause problems for its listing on the Nasdaq Exchange.



Also, all of this volatility makes TWOU stock a bit of a risky investment. Traders will want to keep that in mind before taking a stake in the company.



Investors will want to stick around for more of the most recent stock market news!



We have all of the hottest stock market stories that traders need to know about on Tuesday! That includes warnings of a potential market crash, why Processa Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is up today and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

2U (TWOU) Stock Continues to Surge in Bankruptcy Rally

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) just reported results for the second quarter of 2024.<ul><li>Processa Pharma reported earnings per share of -$1.01. This was below the analyst estimate for EPS of -98 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pcsa-stock-earnings-processa-pharma-for-q2-of-2024/">PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Processa Pharmaceuticals (PCSA – Research Report), H...

Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)

Processa Pharmaceuticals reports GAAP EPS of -$1.01

Processa stock rallies 35% post-market on Phase 2 study update

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals (PCSA – Research Report), retaining the price target o...

Buy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-Cap

PSNL

SOFI

TWOU

Press Releases

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Avenue Therapeutics

Biofrontera

Cingulate

CNS Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Hoth Therapeutics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Pulmatrix

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

TFF Pharmaceuticals

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

HC Wainwright & Co.

Benchmark

Oppenheimer

Processa Pharmaceuticals

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 컨스텔레이션 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.
2. 리바이 스트라우스 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>)는 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B0%94%EC%9D%B4-%EC%8A%A4%ED%8A%B8%EB%9D%BC%EC%9A%B0%EC%8A%A4%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%80-%EC%97%87%EA%B0%88%EB%A6%B0-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%B0%9C%ED%91%9C/" target="_blank" rel="noopener">3분기 이익이 예상보다 좋았지만</a> 매출은 예상에 미달했다고 발표했다. 이 회사는 2024 회계연도 조정된 주당 이익을 1.17달러에서 1.27달러 사이로 예상하고 있으며, 이는 1.25달러의 예상치와 비교된다. 리바이 스트라우스의 주식은 애프터 마켓에서 10.9% 하락하여 18.76달러에 거래되고 있다.
3. 분석가들은 앤지오다이내믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>)가 최근 분기에 주당 15센트의 손실을 기록하고 매출이 6,793만 달러일 것으로 예상하고 있다. 이 회사는 개장 전에 실적을 발표할 예정이다. 앤지오다이내믹스의 주식은 애프터 마켓에서 2.1% 상승하여 7.81달러에 거래되었다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>
4. 빅커머스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>)는 트래비스 헤스(Travis Hess)를 CEO로 임명했다. 브렌트 벨름(Brent Bellm)은 더 이상 회사의 CEO 또는 이사회 의장을 맡지 않는다. 빅커머스의 주식은 애프터 마켓에서 1.4% 상승하여 5.75달러에 거래되고 있다.
5. 프로세사 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>)의 주식은 회사가 NGC-Cap의 2상 시험을 위한 첫 번째 환자를 투여했다고 발표한 후에 수요일 애프터 마켓에서 급등했다. 프로세사 파마슈티컬스의 주식은 애프터 마켓에서 3% 상승하여 1.37달러에 거래되었다.
이것도 확인해보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">월스트리트의 가장 정확한 애널리스트들이 고배당 소비재 주식 3종목에 대한 의견을 제시</a></li>
</ul>
사진 제공: Constellation Brands
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Processa Pharma

뉴스

에 대한 최신 뉴스 Processa Pharma (NASDAQ:PCSA) 주식

목요일, 10월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌